Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Keimyung Univ. HDAC6 compound 6e
- Development stage
- Unknown
- Lead developer
- Keimyung University
01
Overview
Keimyung Univ. HDAC6 compound 6e: sourced facts only. name: "In particular, compound 6e shows a significant inhibitory activity against both HDAC6 and Hsp90 with IC50 values of 106 nM and 61 nM, respectively." [PMID:35834905]; target: "In particular, compound 6e shows a significant inhibitory activity against both HDAC6 and Hsp90 with IC50 values of 106 nM and 61 nM, respectively." [PMID:35834905]; developer: "College of Pharmacy, Keimyung University, Daegu, 704-701, South Korea." [PMID:35834905]; stage: "In addition, compound 6e successfully achieved significant tumor growth inhibition in H1975 NSCLC xenograft model without noticeable abnormal behavior, body weight changes, and apparent ocular toxicity." [PMID:35834905]
02
Targets
HDAC6 (Histone deacetylase 6)
Beyond the preview
Go deeper on Keimyung Univ. HDAC6 compound 6e.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Keimyung Univ. HDAC6 compound 6e.